Publicaciones en las que colabora con Juan Luis García Hernández (35)

2016

  1. Integrative analysis of DNA copy number, DNA methylation and gene expression in multiple myeloma reveals alterations related to relapse

    Oncotarget, Vol. 7, Núm. 49, pp. 80664-80679

  2. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial

    The Lancet Oncology, Vol. 17, Núm. 8, pp. 1127-1136

  3. Post-transcriptional modifications contribute to the upregulation of cyclin D2 in multiple myeloma

    Clinical Cancer Research, Vol. 22, Núm. 1, pp. 207-217

2011

  1. Deficient spindle assembly checkpoint in multiple myeloma

    PLoS ONE, Vol. 6, Núm. 11

2010

  1. Immunomodulatory effect of 5-azacytidine (5-azaC): Potential role in the transplantation setting

    Blood, Vol. 115, Núm. 1, pp. 107-121

  2. P53 deletion may drive the clinical evolution and treatment response in multiple myeloma

    European Journal of Haematology, Vol. 84, Núm. 4, pp. 359-361

2009

  1. Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q- syndrome

    Leukemia, Vol. 23, Núm. 4, pp. 664-672

  2. Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors

    Leukemia, Vol. 23, Núm. 8, pp. 1515-1527

2006

  1. Geographic differences in the incidence of cytogenetic abnormalities of acute myelogenous leukemia (AML) in Spain

    Leukemia Research, Vol. 30, Núm. 8, pp. 943-948

2005

  1. Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia

    Leukemia, Vol. 19, Núm. 3, pp. 402-409

  2. Hematological, immunophenotypic, and cytogenetic characteristics of acute myeloblastic leukemia with trisomy 11

    Cancer Genetics and Cytogenetics, Vol. 160, Núm. 1, pp. 68-72

  3. Mobilisation with G-CSF in healthy donors promotes a high but temporal deregulation of genes [7]

    Leukemia

2004

  1. Heterogeneity of structural abnormalities in the 7q31.3∼q34 region in myeloid malignancies

    Cancer Genetics and Cytogenetics

  2. Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma

    Blood, Vol. 104, Núm. 9, pp. 2661-2666

  3. The value of flourescence in situ hybridization for the detection of 11q in multiple myeloma

    Haematologica, Vol. 89, Núm. 10, pp. 1213-1218

2003

  1. Abnormalities on 1q and 7q are associated with poor outcome in sporadic Burkitt's lymphoma. A cytogenetic and comparative genomic hybridization study

    Leukemia, Vol. 17, Núm. 10, pp. 2016-2024

  2. Imatinib mesylate elicits positive clinical response in atypical chronic myeloid leukemia involving the platelet-derived growth factor receptor beta [5]

    Blood

  3. Multicolor flourescence in situ hybridization studies in multiple myeloma and monoclonal gammopathy of undetermined significance

    Hematology Journal, Vol. 4, Núm. 1, pp. 67-70

2001

  1. Applying DOP-PCR to genomic typing of HLA class II

    European Journal of Immunogenetics, Vol. 28, Núm. 2, pp. 362

  2. Differences in genetic changes between multiple myeloma and plasma cell leukemia demonstrated by comparative genomic hybridization

    Leukemia, Vol. 15, Núm. 5, pp. 840-845